Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Pfizer in court over Chinese stealing trade secrets

<< Previous

Bullboard Posts

Next >>

Comment by jimsenioron Feb 08, 2023 3:08pm

144 Views

Post# 35275278

RE:RE:RE:RE:RE:RE:RE:RE:Pfizer in court over Chinese stealing trade secrets

@itntdf. G'day mate. Perhaps we should take the couched admission that AN is an integral part of any deal; we do not know how that will unfold, and frankly we have no idea the stage of any deals and if in fact there are any deals. Many unknowns. I would assume that most pharma deals have more than one party in the takeover target, and they have various solutions. AN will benefit if there is a deal.

I do think there will be a deal; no clue when nor how much.

<< Previous

Bullboard Posts

Next >>

Who, why, and what of the great "Crypto Surge"